SA biotech encounters more regulatory hurdles to U.S. market than in Europe

W. Scott Bailey
SA biotech encounters more regulatory hurdles to U.S. market than in Europe

Nearly three years after taking its novel medical device to market in Europe, the Alamo City company is still working to clear U.S. regulatory roadblocks.